Yan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Liu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Mei Zhou
Beijing Anzhen Hospital, Capital Medical University
3 shared publicationsShijuan Gao
Beijing Anzhen Hospital, Capital Medical University
3 shared publicationsJie Du
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
2 shared publications- Jie Du
Beijing Anzhen Hospital, Capital Medical University
2 shared publications Shuai Zheng
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
2 shared publicationsYulin Li
Beijing Anzhen Hospital, Capital Medical University
2 shared publications
Latest Publications
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (6) , C1716-C1729
Immunoproteasome subunit PSMB8 promotes skeletal muscle regeneration by regulating macrophage phenotyping switch in mice
The immunoproteasome subunit, PSMB8, is essential for efficient muscle regeneration and may be a new therapeutic target for age-related muscle atrophy.
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (6) , C1716-C1729
Immunoproteasome subunit PSMB8 promotes skeletal muscle regeneration by regulating macrophage phenotyping switch in mice
The immunoproteasome subunit, PSMB8, is essential for efficient muscle regeneration and may be a new therapeutic target for age-related muscle atrophy.
- Open Access
- 1 January 2025
- Published by Aging and Disease in Aging and disease
- Vol. 16 (1) , 321-344
Senescent T Cells in Age-Related Diseases
Age-induced alterations in human immunity are often considered deleterious and are referred to as immunosenescence. The immune system monitors the number of senescent cells in the body, while immunosenescence may represent the initiation of systemic aging. Immune cells, particularly T cells, are the most impacted and involved in age-related immune function deterioration, making older individuals more prone to different age-related diseases. T-cell senescence can impact the effectiveness of immunotherapies that rely on the immune system's function, including vaccines and adoptive T-cell therapies. The research and practice of using senescent T cells as therapeutic targets to intervene in age-related diseases are in their nascent stages. Therefore, in this review, we summarize recent related literature to investigate the characteristics of senescent T cells as well as their formation mechanisms, relationship with various aging-related diseases, and means of intervention. The primary objective of this article is to explore the prospects and possibilities of therapeutically targeting senescent T cells, serving as a valuable resource for the development of immunotherapy and treatment of age-related diseases.
- 1 January 2025
- Published by Aging and Disease in Aging and disease
- Vol. 16 (1) , 321-344
Open AccessSenescent T Cells in Age-Related Diseases
Age-induced alterations in human immunity are often considered deleterious and are referred to as immunosenescence. The immune system monitors the number of senescent cells in the body, while immunosenescence may represent the initiation of systemic aging. Immune cells, particularly T cells, are the most impacted and involved in age-related immune function deterioration, making older individuals more prone to different age-related diseases. T-cell senescence can impact the effectiveness of immunotherapies that rely on the immune system's function, including vaccines and adoptive T-cell therapies. The research and practice of using senescent T cells as therapeutic targets to intervene in age-related diseases are in their nascent stages. Therefore, in this review, we summarize recent related literature to investigate the characteristics of senescent T cells as well as their formation mechanisms, relationship with various aging-related diseases, and means of intervention. The primary objective of this article is to explore the prospects and possibilities of therapeutically targeting senescent T cells, serving as a valuable resource for the development of immunotherapy and treatment of age-related diseases.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 327 (4) , C1012-C1022
PALMD haploinsufficiency aggravates extracellular matrix remodeling in vascular smooth muscle cells and promotes calcification
We found that PALMD haploinsufficiency causes extracellular matrix dysregulation, reduced PALMD expression links to vascular calcification, and PALMD mutations may lead to the risk of both calcific aortic valve stenosis and vascular calcification.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 327 (4) , C1012-C1022
PALMD haploinsufficiency aggravates extracellular matrix remodeling in vascular smooth muscle cells and promotes calcification
We found that PALMD haploinsufficiency causes extracellular matrix dysregulation, reduced PALMD expression links to vascular calcification, and PALMD mutations may lead to the risk of both calcific aortic valve stenosis and vascular calcification.
- 1 February 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 326 (2) , C647-C658
Activation of the alternative complement pathway modulates inflammation in thoracic aortic aneurysm/dissection
The alternative complement pathway promoted the development of TAAD by recruiting infiltrating inflammatory cells. Targeting the alternative pathway may thus constitute a strategy for preventing the development of TAAD.
- 1 February 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 326 (2) , C647-C658
Activation of the alternative complement pathway modulates inflammation in thoracic aortic aneurysm/dissection
The alternative complement pathway promoted the development of TAAD by recruiting infiltrating inflammatory cells. Targeting the alternative pathway may thus constitute a strategy for preventing the development of TAAD.
- 12 April 2022
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 15 (5) , 959-970
Fibroblast-Secreted Phosphoprotein 1 Mediates Extracellular Matrix Deposition and Inhibits Smooth Muscle Cell Contractility in Marfan Syndrome Aortic Aneurysm
Fibrillin 1 (Fbn1) mutation causes Marfan syndrome (MFS) with thoracic aortic aneurysm (TAA) as the main complication. The mechanisms for extracellular matrix (ECM) homeostasis disruption in MFS TAA are unclear. Here, we found ECM-related gene secreted phosphoprotein 1 (Spp1) increased in Fbn1C1041G/+ mice using transcriptome sequencing and a distinct fibroblast subcluster with Spp1 as the strongest marker was identified with analysis of the MFS mouse aortic single-cell sequencing dataset. Immunostaining confirmed elevated Spp1 in adventitial fibroblasts, and Spp1 might regulate fibroblast and smooth muscle cell (SMC) communication primarily through Itga8/Itgb1. Then, we observed Spp1 reduced contractile genes Acta2 and Tagln expression in SMCs and increased collagen expression in fibroblasts, which might contribute to TAA development. Finally, we also found elevated SPP1 plasma level was associated with an increased risk of TAA in patients. Therefore, SPP1 may serve as a biomarker and therapeutic target for TAA. Graphical abstract
- 12 April 2022
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 15 (5) , 959-970
Fibroblast-Secreted Phosphoprotein 1 Mediates Extracellular Matrix Deposition and Inhibits Smooth Muscle Cell Contractility in Marfan Syndrome Aortic Aneurysm
Fibrillin 1 (Fbn1) mutation causes Marfan syndrome (MFS) with thoracic aortic aneurysm (TAA) as the main complication. The mechanisms for extracellular matrix (ECM) homeostasis disruption in MFS TAA are unclear. Here, we found ECM-related gene secreted phosphoprotein 1 (Spp1) increased in Fbn1C1041G/+ mice using transcriptome sequencing and a distinct fibroblast subcluster with Spp1 as the strongest marker was identified with analysis of the MFS mouse aortic single-cell sequencing dataset. Immunostaining confirmed elevated Spp1 in adventitial fibroblasts, and Spp1 might regulate fibroblast and smooth muscle cell (SMC) communication primarily through Itga8/Itgb1. Then, we observed Spp1 reduced contractile genes Acta2 and Tagln expression in SMCs and increased collagen expression in fibroblasts, which might contribute to TAA development. Finally, we also found elevated SPP1 plasma level was associated with an increased risk of TAA in patients. Therefore, SPP1 may serve as a biomarker and therapeutic target for TAA. Graphical abstract